Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Company Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $141,150.00. Following the transaction, the insider directly owned 1,599,208 shares of the company’s stock, valued at $15,048,547.28. The trade was a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total value of $127,350.00.
• On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.02, for a total value of $120,300.00.

Xeris Biopharma Trading Down 1.8%

Shares of XERS traded down $0.17 during midday trading on Friday, hitting $9.08. 1,375,716 shares of the stock were exchanged, compared to its average volume of 1,988,684. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $11.33. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The stock has a fifty day simple moving average of $8.45 and a 200 day simple moving average of $7.29. The firm has a market cap of $1.66 billion, a P/E ratio of -82.55 and a beta of 0.53.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in XERS. Walleye Capital LLC acquired a new stake in shares of Xeris Biopharma during the second quarter worth $4,841,000. Canada Pension Plan Investment Board purchased a new position in Xeris Biopharma in the second quarter worth $1,736,000. Legal & General Group Plc acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth $15,941,000. Rice Hall James & Associates LLC purchased a new position in shares of Xeris Biopharma in the 1st quarter valued at about $1,456,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after purchasing an additional 225,602 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on XERS shares. Leerink Partners boosted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Barclays upped their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma presently has an average rating of “Hold” and an average price target of $12.80.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.